Close menu

November 1st, 2023 | 06:10 CET

More than 300% share price opportunity: BioNTech, Morphosys and Cardiol Therapeutics

  • Biotechnology
  • CBD
Photo credits: BASF SE

Study results, along with acquisitions by Big Pharma, are the drivers of biotech company share prices. However, in the current challenging stock market environment, even positive data can be overlooked. But this opens up opportunities for investors with a little more staying power. Sooner or later, the information is recognized, and stock prices rise, or a pharmaceutical giant makes a move. At BioNTech, for example, the price reaction to the long-awaited news from the cancer pipeline has failed to materialize. Analysts are also cautious. Cardiol Therapeutics is a different story. The Canadians have taken on the fight against heart disease and are making significant progress in their research. The share had more than doubled to EUR 1.08 by the summer. Several analysts see the current setback as a buying opportunity. Experts are also giving the thumbs up to German biotech pioneer Morphosys.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Cardiol Therapeutics: Deep pockets and 300% potential

    Both the analysts at Canada's Leede Jones Gable and Germany's First Berlin see more than 300% upside potential for Cardiol Therapeutics' stock. Leede Jones Gable has set a price target of USD 3.25, while their counterparts in Berlin have set a price target of EUR 3.30. The biotech share is currently trading at USD 0.80.

    In recent weeks, there has been a positive news flow. Most recently, positive results were reported for cannabidiol, the active pharmaceutical ingredient in Cardiol's innovative CRD-38 formulation. It is administered subcutaneously and slows the increase in body and heart weight. It also prevented increases in key cardiac inflammatory and remodeling markers in heart failure. This implies new therapeutic potential for CRD-38 in heart failure.

    Analysts at Leede Jones Gable commented: "Although Cardiol is further advanced in testing the anti-inflammatory cardiovascular activity of CBD in two other medical markets, the Company's progress in testing a subcutaneously injectable formulation of this viscous hydrophobic agent is equally integral to our CRDL investment thesis. We attribute tangible market value to diastolic heart failure as an addressable cardiovascular market for the Company." Cardiol is also advancing in the development of CardiolRx™ for the treatment of recurrent pericarditis (RP) - inflammation of the pericardium - and acute myocarditis (AM) - inflammation of the heart muscle. First Berlin analysts expect positive news from this area before the end of the year. By then, at the latest, the consolidation of the share should be over.

    BioNTech: Buy or Hold?

    Those who had hoped that the positive news from BioNTech's cancer pipeline would ensure a sustained positive share price reaction were caught off guard. The joy lasted only a few days. In the meantime, the share has fallen back below EUR 90. Analysts are also surprisingly calm, and the COVID-19 vaccine still dominates discussions. From JPMorgan's point of view, the BioNTech share is currently not a buy. Uncertainty about future revenues from the COVID-19 vaccine and the value of the product pipeline leaves little room for the stock. Thus, JPMorgan's price target for BioNTech is USD 106.

    UBS's price target is significantly higher. Their analysts believe that the BioNTech share is worth USD 153. Given the current price, however, it is surprising that the recommendation is still only "Neutral". It seems that there is some uncertainty even within their own analysis. For Jefferies, Deutsche Bank, Morgan Stanley and Goldman Sachs, the BioNTech share is currently also only a hold position.

    Morphosys: Buy or sell?

    At Morphosys, analysts are currently in the bull camp. After all, the shares of the German biotech pioneer have gained more than 100% this year and are hovering around EUR 30. JPMorgan still sees a 20% upside. Sales of the blood cancer drug Monjuvi in the USA are exceeding expectations. This increases the chance that the annual target could be too low. For now, the analysts have not raised their estimates, and the price target remains at EUR 36. UBS recommends the Morphosys share with a "Buy", and a price target of EUR 45. According to UBS analysts, Monjuvi's sales are in line with expectations.

    The analysts at Deutsche Bank were not yet convinced by the preliminary figures for the third quarter. They hope for more details in the final quarterly report and left their rating of the Morphosys share at "Hold". The price target is EUR 25, even slightly below the current level.

    Biotech stocks are currently facing challenges, with even positive news having little impact on their prices. Analysts are also cautious about BioNTech and Morphosys. Experts see more upside potential for newcomer Cardiol Therapeutics. If First Berlin is right and there is more positive news soon, then buying Cardiol Therapeutics may prove to be a worthwhile investment.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.


    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.


    Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST

    Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa

    • Mining
    • Gold
    • Commodities
    • Biotechnology
    • airline

    The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!